<DOC>
	<DOCNO>NCT01522547</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose , safety effect induction fetal hemoglobin pomalidomide patient Sickle Cell Disease .</brief_summary>
	<brief_title>Study Determine Maximum Tolerated Dose , Safety Effectiveness Pomalidomide Patients With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Ages 18 60 year , inclusive , time signing informed consent form Clinically significant Sickle Cell Disease ( SCD ) document Sickle Cell Anemia Sickle BetaZero Thalassemia Clinically significant SCD define least 1 documented pain episode per year average past 3 year one episode active leg ulcer , priapism , acute chest syndrome past 3 year Failed achieve least absolute 5 % increase hemoglobin F take Hydroxyurea ( HU ) unable tolerate HU describe treat physician may include limited lack efficacy ( people continue pain episode 2 time year acute chest multiorgan failure syndromes episode priapism ) , severe side effect HU ( severe side effect include significant myelosuppression ; skin cancer ; cytotoxicity evidence gastrointestinal symptom , dermatological reaction , hepatic enzyme elevation , pulmonary fibrosis neurological disturbance ) , refusal hydroxyurea therapy inform patient Able adhere study visit schedule protocol requirement Females must surgically sterile ( post hysterectomy bilateral oophorectomy ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) Male subject must agree use latex condom sexual contact female child bear potential ( FCBP ) study drug treatment , dose interruption , least 28 day follow discontinuation study drug even undergone successful vasectomy . Counseling requirement latex condom use sexual contact FCBP potential risk fetal exposure must conduct minimum every 28 day . Male subject must agree abstain donate semen sperm take study drug 28 day stop study drug . Both male female must agree abstain donate blood take study drug 28 day stop study drug . Both male female must agree share study drug counsel potential risk fetal exposure . Known positive status human immune virus ( HIV ) , Hepatitis B ; acute/chronic , active Hepatitis C Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form Females childbearing potential , pregnant lactate female Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Subjects unlikely comply birth control , medication dosing , study visit requirement Subjects severe life threatening , active , unresolved infection Any follow laboratory abnormality derive Screening Visit : Platelet count white blood cell count ( WBC ) less low limit normal ( LLN ) Total hemoglobin less equal 6.0 g/dL Hemoglobin A ( HbA ) transfusion great 20 % baseline Creatinine great Upper Limit Normal ( ULN ) Alanine Aminotransferase / Serum Glutamic Pyruvic Transaminase ( ALT/SGPT ) great 3 x ULN Total bilirubin great 10 mg/dL Subjects chronic transfusion program History noncatheter relate Deep Vein Thrombosis ( DVT ) stroke Chronic symptomatic constipation History cancer ( except basal cell squamous cell carcinoma carcinoma situ cervix breast ) unless subject free disease least three year . Use agent induce fetal hemoglobin within 90 day ( three month ) Day 1 ( i.e . HU , butyrates , decitabine , 5azacytidine , erythropoietin ) Use experimental drug treatment within 30 day first dose study drug History allergic reaction thalidomide lenalidomide Prior desquamating ( blister ) rash take thalidomide lenalidomide Greater equal Grade 2 neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Pomalidomide</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Fetal Hemoglobin</keyword>
</DOC>